Lee S, Zhou J, Leung KSK, et al. Comparison of sodium-glucose Cotransporter-2 inhibitor and dipeptidyl Peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients: a propensity score-matched study in Hong Kong. Cardiovasc Drugs Ther. 2023;37(3):561–9. https://doi.org/10.1007/s10557-022-07319-x.

Article  CAS  PubMed  Google Scholar 

Lai S-W. Comment on comparison of sodium-glucose Cotransporter-2 inhibitor and dipeptidyl Peptidase-4 inhibitor on the risks of new-onset atrial fibrillation, stroke and mortality in diabetic patients. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07527-z.

Article  PubMed  Google Scholar 

Wolff G, Lin Y, Akbulut C, et al. Meta-analysed numbers needed to treat of novel antidiabetic drugs for cardiovascular outcomes. ESC Heart Fail. 2023;10(1):552–67. https://doi.org/10.1002/ehf2.14213.

Article  PubMed  Google Scholar 

Zhou J, Lee S, Leung KSK, et al. Incident heart failure and myocardial infarction in sodium-glucose cotransporter-2 vs. dipeptidyl peptidase-4 inhibitor users. ESC Heart Fail. 2022;9(2):1388–99. https://doi.org/10.1002/ehf2.13830.

Article  PubMed  PubMed Central  Google Scholar 

Hammer A, Niessner A, Sulzgruber P. Early initiation of SGLT2 inhibitors in acute heart failure: a focus on diuresis and renal protection. Cardiovasc Drugs Ther. 2023. https://doi.org/10.1007/s10557-023-07512-6.

Article  PubMed  Google Scholar